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Treatment of cis/trans-[PtCl2(N≡CR)2] 1 (R = CH3 (1a), C2H5 (1b), C6H5 (1c), CH2C6H4(p-CH3) (1d)) with 
1,3-diiminoisoindoline 2 gives access to the corresponding symmetrical (1,3,5,7,9-pentaazanona-1,3,6,8-tetraenato) platinum(II) 
complexes [PtCl{NH=C(R)N=C(C6H4)NC=NC(R)=NH}] 3a-d, in good yields (65–77%). The compounds 3a-d have been 
characterized by IR, 1H, 13C and DEPT-135 NMR spectroscopies, ESI-MS and elemental analyses. GIAO/DFT studies have 
been performed to confirm the molecular structure of the platinum(II)-pincer 3d by comparing the experimental and theoretical 
1H and 13C NMR chemical shifts, and it has shown good correlations between experimental and calculated chemical shifts for 
proton and carbon with correlation coefficients of 0.9947 and 0.9968, respectively. Molecular electrostatic potential is used to 
investigate the nucleophilic or electrophilic regions in the molecule 3d. The antimicrobial activities of compounds 3a-d are 
determined against different bacterial pathogens and yeasts. No toxicity is recorded against Artemia saline as a test organism for 
3a-c, while moderate toxicity is found for 3d at 0.62 µM. Comparable antitumor activities are found for 3a-d against human 
colon HCT116 and human breast (MCF-7) cancer cell lines. The complexes 3a-d have shown good binding affinities to 
ct-DNA in the range of 6.00105 to 8.33105 and the conducted molecular docking studies suggest an intercalation mode of 
binding with DNA by the isoindole fragment of the ligands. Overall, this class of tridentate ligands have shown good potential 
in designing platinum(II) complexes with promising biological and anticancer activities. Moreover, the presence of the side 
chains on the ligands provides great design flexibility by introducing some chemical and/or physical characteristics. 
Keywords: Platinum(II) complexes, Pincer ligands, Antimicrobial, Anticancer, DNA-binding, Molecular docking 
Cisplatin has gained clinical approval in 1978 as a 
drug in treating some types of cancer and around 50% 
of the chemotherapeutic protocols include cisplatin1. 
However, its severe side effects motivated researchers 
to design alternatives with enhanced features through 
several approaches including the alteration of the 
coordination sphere around the platinum-metal centre. 
Carboplatin (clinically approved in 1986) and 
oxaliplatin (clinically approved in 1996) were 
introduced as alternatives with less side effects with 
comparable effectiveness against some cancer cell 
lines but with some problems involving the solubility 
and delivery2. Recently, there is an increasing interest 
in the preparation of platinum(II) compounds bearing 
bidentate N-donor ligands as drugs; these compounds 
display good bioactivity combined with low toxicity. 
Research has been paying attention to pyridine-based 
platinum(II) compounds due to their similar or better 
cytotoxicity compared to cisplatin against some 
cancer cell lines3. Planar ligands are advantageous as 
their metal-complexes have low tendencies towards 
thiol deactivation4. Remarkable anticancer activities 
were highlighted for a range of platinum(II) 
compounds functionalized with pyridyl Schiff bases 
and their mechanism of action was induced by 
apoptosis5. Platinum(II) compounds containing amino 
pyridine derivatives showed an intercalation mode of 
binding with DNA with excellent cytotoxicity 
compared to cisplatin when tested against three 
different tumor cell lines6. Cytotoxicity against breast, 
lung and human cervical cancer cell lines was 
reported for a range of platinum(II) compounds with 
amino pyridine ligands and found to be better than 
that reported for cisplatin6b. Imino-quinolyl containing 




platinum(II) complexes were assessed for their 
anticancer properties in vitro and found to be 
cytotoxic against human colon (HT-29) and human 
breast (MCF-7) cancer cell lines7. Tridentate ligands 
have been employed recently in designing anticancer 
platinum complexes. In the past few years, many 
platinum complexes bearing π-conjugated polypyridyl 
ligands have been under enormous interest due to 
their anticancer activities8. This interest stems from 
the ability of the planar aromatic ligands to interact 
noncovalently, specifically the intercalation mode of 
binding between base pairs in the DNA. Lippard et al. 
reported the first X-ray structure of intercalating 
[Pt(terpy)(S-CH2CH2-OH)] between adjacent DNA 
base pairs, causing the unwinding of the DNA9. More 
complexes with other leaving groups bind covalently 
to the guanine bases similar to cisplatin10. In addition, 
several platinum(II) terpyridine complexes with 
different functionalized thiol ligands have been 
synthesized and found to be active against the murine 
leukemia cell line (L1210)11. Despite the parent 
complex with labile chloro which found to be 
ineffective, other variations to groups attached to 
platinum such as picoline and acetylides have  
better anticancer activities12. Groove binding and 
highly active anticancer agent was obtained  
when the terpyridine ligand was decorated with  
tert-butyl group13 (Fig. 1). 
Herein, we are examining for the first time our 
neutral platinum(II) complexes with isoindole-
containing tridentate ligands14 as DNA-intercalating 
agents and evaluating their antimicrobial, toxicity and 
antitumor activities. The tridentate ligands have the 
isoindole planar fragment with two side alkyl or aryl 
side chains; the alkyl and aryl arms can be utilized to 
tune the dimensions of the complexes, in addition  
to their contributions in some physical (e.g., 
hydrophilicity, hydrophobicity, etc.) and chemical 
(e.g., noncovalent interactions) properties. 
 
Materials and Methods 
 
Instrumentations 
1H, 13C and DEPT-135 NMR spectra (in CDCl3) 
were measured on a Bruker Avance III HD 600 MHz 
(Ascend™ Magnet) spectrometer at ambient 
temperature. 1H, 13C and DEPT-135 chemical shifts 
() are expressed in ppm relative to trimethylsilane 
(TMS). Infrared spectra (IR) were recorded on an 
Alpha Bruker FT-IR instrument in KBr pellets. High 
resolution electrospray ionization mass spectrometry 
(ESI-MS) spectra were recorded using impact II™ 
mass spectrometer from Bruker; the mass 
spectrometry is reported as m/z. In our previously 
work, the synthesis of (1,3,5,7,9-Pentaazanona-
1,3,6,8-tetraenato) platinum(II) complexes [PtCl 
{NH=C(R)N=C(C6H4)NC=NC(R)=NH}] (R = CH3 
(3a), C2H5 (3b), C6H5 (3c)) was described14. 
 
Preparation of the nitrile platinum(II) complex cis/trans-
[PtCl2(N≡CCH2C6H4(p-CH3))2] 1d and its reactions with  
1,3-diiminoisoindoline 2 
 
Reaction of platinum(II) chloride with p-tolylacetonitrile 
Platinum(II) chloride (200 mg, 0.752 mmol)  
was added at room temperature to p-tolylacetonitrile 
(5 mL), and the mixture was heated at 70 °C for 8 h. 
During the course of the reaction the green gray PtCl2 
powder was dissolved forming a homogeneous light 
yellow solution which indicated the formation of 
 
 
Fig. 1 — Clinically approved platinum drugs and different classes of potential anticancer pyridyl-containing platinum complexes 




cis/trans-[PtCl2(N≡CCH2C6H4(p-CH3))2] 1d complex. 
The obtained solution was used for the next step 
without further purification. 
 
Reaction of the nitrile platinum(II) complex cis/trans-
[PtCl2(N≡CCH2C6H4(p-CH3))2] 1d with 1,3-diiminoisoindoline 2 
A solution of 1d (0.532 mmol) in p-tolyl-
acetonitrile/chloroform (10 mL, v/v) was added at 
room temperature to 1,3-diiminoisoindoline 2  
(77.2 mg, 0.532 mmol), and the mixture was refluxed 
for 2 h whereupon the solvent was removed in vacuo. 
The crude residue was purified by column 
chromatography on silica (chloroform as the eluent), 
followed by evaporation of the solvent in vacuo to 
give the final [PtCl{NH=C(CH2C6H4(p-CH3))N=C 
(C6H4)NC=NC(CH2C6H4(p-CH3))=NH}] 3d product. 
Yield: 77%. IR (cm−1): 3440 (NH), 1621 (C=N). 1H 
NMR, δ (ppm): 2.35 (s, 6H, CH3), 4.01 (s, 4H, CH2), 
7.20 (d, 4H, JHH 7.6 Hz, CHaromatic), 7.23 (d, 4H, JHH 
8.5 Hz, CHaromatic), 7.73 (bs, 2H, CHaromatic), 8.22 (bs, 
2H, CHaromatic), 9.69 (s, br, 2H, NH). 
13C NMR,  
δ (ppm): 21.2 (CH3), 47.4 (CH2), 123.3, 127.8, 127.9, 
129.6, 129.8, 130.0, 130.2, 132.1 (CHaromatic), 137.6, 
137.8, 137.9, 138.8 (Caromatic), 153.3 and 161.6 (C=N). 
DEPT-135 NMR, δ (ppm): 21.2 (CH3), 47.4 (CH2), 
123.3, 127.8, 127.9, 129.6, 129.8, 130.0, 130.2, 132.1 
(CHaromatic). Anal. Calcd for C26H24ClN5Pt (636.137): 
C, 49.02; H, 3.80; N, 10.99. Found: C, 49.38; H, 3.55; 
N, 11.21. ESI+-MS: m/z 635.444 [M-1]+. 
 
Computational methods 
The DFT calculations were performed by Becke's 
three-parameter exchange functional with Lee-Yang-
Parr (LYP) correlation functional. Gaussian 09 
software15 were used to performed full geometry 
optimizations of the compound 3d at the B3LYP level 
of theory using an LANL2DZ for platinum atom and 
6-311G* basis set on all other atoms. The 
optimization confirmed with absence of negative 
frequency. The Gauge-Independent Atomic Orbital 
(GIAO) method was used at the B3LYP 
/LANL2DZ/6-311G* level of theory to calculate the 
NMR chemical shifts with Polarizable Continuum 
Model (PCM). Single point TD-DFT computations 
were performed in order to obtain the vertical 
electronic transition energies. The softwares 
Chemcraft16 and Multiwfn17 were used for the 
analysis of Gaussian 09 output files. 
 
Antimicrobial activity 
The antibacterial activities of the tested compounds 
3a-d against Enterococcus feacalis, Staphylococcus 
aureus (MRSA), Pseudomonas aeruginosa, Salmonella 
enterica, Escherichia coli and Klebsiella pneumonia 
were determined using paper disc diffusion method. 
These bacteria were obtained from King Faisal 
Hospital and Research Center, Jeddah, Saudi Arabia on 
blood agar and preserved on nutrient agar slants at 4 °C 
until used. A paper disk, 7 mm diameter, loaded with 
the tested material (15 µg/disc) was put on Mueller 
Hinton agar (Sigma-Aldrich) plate, inoculated with the 
tested bacterium (100 µL of 4×106 CFU/mL). After 
incubation at 37 °C for 2 days, mean inhibition zone 
diameter of three reading was calculated in mm18. The 
antifungal activity against two species of Candida was 
detected on PDA medium and the incubation was 
carried out at 37 °C for 4 days. The minimum 
inhibitory concentrations (MICs) were determined 
using broth microdilution method19. 
 
Cell toxicity using Artemiasalina as a test organism 
Artemia-based toxicity assay are cheap, 
continuously available, simple and reliable, and are 
thus an important routine work of toxicity screening. 
Brine shrimp lethality test was used to determine  
cell toxicity of the tested materials 3a-d using 
Artemiasalina as a test organism20. After egg 
hatching, larvae were collecting and certain numbers 
were treated with different concentrations of the 
tested materials. After 8 h, surviving or dead larvae 




Two cell lines, human colon cancer HCT116 and 
human breast cancer MCF-7 were cultured in 
McCoy's 5a and DMEM medium, respectively, 
supplemented with 10% (v/v) FBS and 100 U/mL of 
penicillin, 100 μg/mL streptomycin at 37 °C in CO2 
incubator. Cells were incubated with various 
compounds for the indicated periods of time and 
cytotoxicity was determined by means of the 
colorimetric assay MTT (3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide)23. 
 
Statistical analyses  
The data were expressed as means plus standard 
deviation and one-way ANOVA was used for 
statistical analysis to compare the results. Tukey test 
(t- test) was considered significant at p ≤ 5%. 
 
DNA binding studies 
The stock solution of ct-DNA was prepared in 
distilled water and its concentration was identified 




from the UV-visible absorbance values at 260 nm 
using the reported  value of 6600 M−1 cm−1, while 
ratio of absorbance at 260 to that at 280 nm is 1.8 (to 
ensure DNA is free from protein impurities)24. The 
concentration of the obtained ct-DNA is calculated to 
be around 5700 μM when 1 mg was dissolved in  
1 mL of water. Evaluation of the binding constants 
between the platinum(II) complexes 3a-d and ct-DNA 
were achieved by the gradual increase in the ct-DNA 
concentration to a solution of the complexes  
(100 mM) while maintaining the pH at 7.4, and using 
a buffer system (5 mM Tris-HCl/50 mM NaCl). The 
titration process was followed by the spectroscopic 
responses in absorption spectroscopy at 270 nm25. The 
binding constants (Kb) were calculated from the 
plotting of Ao/(A − Ao) against 1/[DNA] in accordance 
to Benesi-Hildebrand equation: 
 𝐴𝐴 − 𝐴 =  𝜀𝜀 − 𝜀 +  𝜀𝜀 − 𝜀  ×  1𝐾 𝐷𝑁𝐴  
 … (1) 
 
Ao/(A − Ao) is plotted against 1/[DNA] and Kb 
values were calculated from the ratio of the intercept 
to slope26, where Ao and A are the absorbance values 
of the compounds in the absence and presence of  
ct-DNA, respectively27. 
In order to determine the binding mode of 
complexes 3a-d, changes in viscosity were measured 
by keeping the ct-DNA concentration constant and 
varying the concentration of platinum(II) complexes. 
Viscosity experiments were carried out using 
Calibrated-Cannon-Fenske Routine viscometer 
universal size 450 at 25 °C. Flow time was measured 
for each sample three times, and an average flow time 
was calculated. The data were plotted as (η/η0)1/3 
versus [complex]/ [DNA] ratio, where η and η0 are the 
relative viscosity of DNA in the presence and absence 
of entitled complexes, respectively28. 
 
Molecular docking studies 
Molecular docking studies were conducted by 
Molecular Operating Environment (MOE) 2008.10 
(Moe source: Chemical Computing Group Inc., 
Quebec, Canada, 2008), a Gaussian contact surface 
around the binding sites were drawn, then the surface 
enclosed the van der Waals surface. Finally, docking 
studies were done to assess the binding free energy of 
the complexes inside the DNA. The docking scores 
were initially obtained utilizing London dG scoring 
function in MOE software and were upgraded using 
two unrelated refinement methods. The Grid-Min 
pose and the force-filed were employed to check that 
the refined poses of the complexes meet the correct 
geometrical conformations. Bonds’ rotations were 
allowed and the best five binding poses were directed 
for analysis. The docking poses of the platinum(II) 
complexes 3a-d and the co-crystallized structure of 
the ct-DNA were docked together and RMSD values 
were used to evaluate the best binding pose. 
 
Results and Discussion 
 
Reactions of bis(nitrile)platinum(II) complexes 1 with 1,3-
diiminoisoindoline 2 
In a previous work, several methodologies were 
used to synthesise metal-complexes containing C–N 
and/or C–O bonds via addition of nucleophiles29 or 
1,3-dipoles30 to metal-activated organonitriles. Recently, 
we have reported that 1,3-diiminoisoindoline displays 
good nucleophilic properties toward additions to 
various bis(nitrile) platinum(II) complexes cis/ 
trans-[PtCl2(N≡CR)2]14. The 1,3-diiminoisoindoline 
contains two sp2-N nucleophiles and one endocyclic 
sp3-N moiety which can be deprotonated and then 
coordinated to platinum(II) centre. In addition, the 
nucleophilic additions of imino groups to both nitrile 
ligands furnishes (1,3,5,7,9-pentaazanona-1,3,6,8-
tetraenato)platinum(II) compounds (Fig. 2). 
The platinum(II)-bound nitriles cis/trans-[PtCl2 
(N≡CR)2]1 (R = CH3 (1a), C2H5 (1b), C6H5 (1c), 
CH2C6H4(p-CH3) (1d)) were synthesised, in excellent 
yields (ca. 90%), by reaction of platinum(II) chloride 
with the respective nitriles. Treatment of 1a-d with 
1,3-diiminoisoindoline HN=CC6H4C(NH)= NH 2, in 
refluxing chloroform for 2 h, affords symmetrical 
(1,3,5,7,9-pentaazanona-1,3,6,8-tetraenato) platinum 
(II) compounds [PtCl{NH=C(R)N=C(C6H4) NC=NC 
(R)=NH}] 3a-d in good yields (65–77%) (Scheme 1). 
The IR spectrum of 3d does not show υ(NC) 
values (2250-2350 cm-1 range), while new bands due 
to υ(NH) and υ(N=C) are observed at 3440 and 
1621cm-1, respectively. In the 1H NMR spectrum of 
3d, the signal of the two methyl groups (CH3) appears 
 
 
Fig. 2 — 1,3-Diiminoisoindoline and 1,3,5,7,9-pentaazanona-
1,3,6,8-tetraenato complex 




as a singlet at  2.35; the signals of the four aromatic 
protons of the isoindole moiety appear as two broad 
signals at  7.73 and 8.22, respectively; and the two 
NH protons are exhibited at  9.69. The 13C NMR 
spectrum of 3d shows the characteristic signals of the 
imine N=C groups at  153.3 and 161.6,  
and the absence of the nitrile NC resonance at  
118 ppm confirms that the addition of 1,3-
diiminoisoindoline 2 occurs to both p-tolylacetonitrile 





The structure of the complex 3d was optimized 
using DFT at the B3LYP/LANL2DZ/6-311G* level 
of theory (Fig. 3). Selected bond lengths, bond and 
torsion angles are shown in Table 1. These data  
are in agreement with the experimental of  
similar complexes14. The square-planar coordination 
environment of the platinum(II) centre is defined by 
the monoanionic tridentate N^N^N ligand and one 
chloride anion, comprising two fused six-membered 
metallacycles defined by [N^C^N^C^N^Pt] atoms. 
 
 
Fig. 3 — Optimized structure of complex 3d 
 
NMR analysis 
The 1H and 13C NMR spectra of the platinum(II) 
complex 3d were recorded experimentally in 
deuterated chloroform and they were calculated using 
B3LYP/LANL2DZ/6-311G* level of theory with 
GIAO approach in chloroform. The chemical shifts 
 
 
Scheme 1 — Synthesis of symmetrical (1,3,5,7,9-pentaazanona-1,3,6,8-tetraenato)platinum(II) complexes 3a-d 
 




for 1H and 13C nuclei in solution and theoretical 
values are shown in Table 2. The chemical shifts in 
the 1H and 13C NMR spectra were assigned with the 
help of DFT calculations of shielding constants. The 
theoretically calculated chemical shifts were in good 
agreement with the experimental ones, and the 
correlation coefficients for 1H were 0.9947 (Fig. 4a) 
with excluding the imine protons because they are 
showing deviations from trend (labile protons), since 
protons attached to nitrogen are solvent and 
environment dependent, it is not easy to compare their 
theoretical values with the experimental ones31. The 
correlation coefficients for 13C were 0.9968 (Fig. 4b). 
 
Molecular orbital analysis 
Frontier molecular orbitals (FMOs) play crucial 
role in the chemical stability, optical properties and 
biological activities of the molecules and also in the 
interactions between atoms. Among these, the highest 
occupied molecular orbital (HOMO) and the lowest 
unoccupied molecular orbital (LUMO) are the most 
important. Fig. 5, showed the electron density of the 
HOMO–2, HOMO–1, HOMO, LUMO, LUMO+1, 
and LUMO+2 molecular orbitals. Analysis of these 
orbitals showed that these orbitals are mainly 
composed of combination of atomic orbitals of the Pt, 
C, N and Cl atoms. The composition of each orbitals 
are shown in Table 3. 
HOMO and LUMO analysis showed that 
composition of HOMO is mainly consisting of 
21.55% dxy of Pt, 5.64% dxz of Pt, and 42.36% Pz of 
Cl ions. While, the LUMO is mainly consisting of 
5.90% dxz of Pt, 13.16% Pz of C6, 12.70% Pz of C7, 
5.86% Pz of C8, 8.28% Pz of N9, 9.00% Pz of N10, 
11.38% Pz of N54 and 11.91% Pz of N56. 
 
Molecular electrostatic potential 
Molecular electrostatic potential (MEP) is used to 
investigate the nucleophilic or electrophilic regions in a 
molecule. The surface of the complex 3d was plotted 
over an optimized electronic structures using 
B3LYP/LANL2DZ/6-311G* as shown in Fig. 6. The 
most positive (blue) regions are localized on hydrogen 
atoms of phenyl rings, showing electrophilic reactivity; 
whereas the most negative (red) regions are observed 
around the chloride ion showing nucleophilic 
reactivity. This result suggest that the chloride ion is 
very important for binding of this molecule with  
DNA in term of nucleophilic or electrophilic attack  
in hydrogen-bonding interactions and for the 
understanding of the process of biological recognition. 
 
Antimicrobial activity 
Multidrug resistant bacteria that resist to at least 
two antibiotics is due to the accumulation of different 
resistant genes and/or increased expression of genes 
that code for multidrug efflux pumps leading to an 
increase in human death every day32. The antibacterial 
activities of compounds 3a-d were determined against 
six different multidrug resistant bacterial pathogens 
and some pathogenic yeasts. Complexes 3a-c showed 
moderate activities against all tested gram negative 
Table 1 — Selected geometric parameters (Å, °) of complex 3d compared to reference14 
Pt1-Cl53 2.411 [2.3178(16)a, 2.3250(17)b] Pt1-N56 2.000 [1.972(5)a, 1.972(5)b] 
Pt1-N54 2.002 [ 1.972(5)a, 1.974(5)b] Pt1-N5 1.983 [1.961(6)a, 1.942(5)b] 
Cl53-Pt1-N54 91.40 [90.66(11)a, 91.67(17)b] N54-Pt1-N56 177.69 [178.7(2)a, 178.5(2)b] 
Cl53-Pt1-N56 90.91 [90.66(11a), 89.73(17)b] N5-Pt1-N56 88.86 [89.34(11)a, 88.9(2)b] 
Cl53-Pt1-N5 179.53 [180.0a, 178.28(16)b] N5-Pt1-N54 88.83[89.34(11)a, 89.7(2)b] 
a reference14a; b reference14b 
 
Table 2 — Comparison of the calculated chemical shifts  
(GIAO B3LYP/6-311G*) with the experimental (in CDCl3)  
for complex 3d 
H C-13 
Atom Exp DFT Atom Exp DFT 
H-13,H-23 8.22 8.30 C-11 161.60 171.11 
H-57 9.69 8.23 C-8 161.60 169.76 
H-42, H-17 7.73 7.88 C-6 153.31 159.63 
H-19 7.24 7.77 C-7 153.31 158.72 
H-40 7.23 7.58 C-50 138.81 143.48 
H-55 9.69 7.42 C-28, C-15 137.88 141.72 
H-52, H-49, H-
38, H-36, H-34 
7.20 7.42 C-14 137.88 141.61 
H-21 7.19 7.30 C-27 137.85 137.79 
H-25, H-26 4.01 4.47 C-41, C-16 132.13 134.20 
H-4 4.01 4.28 C-43 137.60 133.70 
H-3 4.01 4.01 C-48 132.12 133.33 
H-47 2.35 2.78 C-37 130.21 133.15 
H-46, H-32 2.35 2.60 C-18 129.99 132.64 
H-31 2.35 2.30 C-39 129.78 132.36 
H-30, H-45 2.35 2.19 C-51 129.63 132.03 
   C-20 127.95 131.18 
   C-33, C-35 127.81 130.93 
   C-22 123.30 125.30 
   C-12 123.30 125.18 
   C-2 47.40 50.17 
   C-24 47.40 48.16 
   C-44 21.20 19.77 
   C-29 21.20 19.55 
 




bacteria while excellent activities were recorded 
against the three tested gram positive bacterial 
pathogens, Enterococcus faecalis, Staphylococcus 
aureus and MRSA (Table 4). The  mean  diameter  of 
inhibition zones were ranged between 17-22 mm for 
gram positive bacteria and between 10-13 mm for 
gram negative ones. Very weak activity was recorded 
for complex 3d compared to control antibiotic 
(Ampicillin). The antifungal activity against Candida 
albicans and C. tropical were recognized for 
complexes 3c and 3d (Table 5) with MICs ranged 
from 0.05 to 0.1 µM, while complexes 3a and 3b 
 
 




Fig. 5 — Molecular orbital shapes of platinum(II)pincer3d using B3LYP/6-311G* 
 
Table 3 — Composition of atoms in molecular orbitals for complex 3d 
Atom Molecular orbital composition (%) 
 HOMO-2 HOMO-1 HOMO LUMO LUMO+1 LUMO+2 
1(Pt) 4.36 15.13 30.65 8.42 7.54 58.37 
5(N) - 2.00 9.10 - 15.71 10.39 
6(C) - - - 12.52 5.50 - 
7(C) - - - 12.03 6.14 - 
8(C) - - - - 14.20 - 
9(N ) - 11.82 4.27 7.88 - - 
10(N) - 13.47 4.22 8.52 - - 
11(C) - - - - 13.82 - 
12(C) - - - - 7.88 - 
18 (C) 6.69 - - - - - 
20(C) 8.13 - - - - - 
22(C) - - - - 7.59 - 
27(C) 24.23 - - - - - 
28(C) 24.81 - - - - - 
53(Cl) 7.20 36.98 42.73 - - 12.01 
54(N ) - - 2.72 10.36 5.76 6.32 
56(N ) - - 2.82 10.82 5.70 6.43 
 




showed no antifungal activities (data not shown). 
MIC of each compound  was  determined  for  MRSA 
and E. faecalis, the lowest MICs of 3a and 3b (0.03 - 
0.06 µM) were recorded for the two tested bacteria, 
and the MIC of 3c (0.05 µM) was recorded only for 
E. faecalis (Table 6). Similarly, the synthesized  
N-naphtylen diamine platinum(II) chloride inhibited 
bacterial growth and division specially Pseudomonas 
aeruginosa and E. coli at 15 mg/mL33. No toxicity 
was recorded against Artemia saline as a test 
organism for 3a-c, while moderate toxicity was found 
for 3d (Table 6). 
 
Antitumor activity 
The in vitro cytotoxic activities of the compounds 
3a-d were recorded against human colon HCT116 and 
human breast (MCF-7) cancer cell lines with IC50 
about 2.426-3.955 µM (Table 6). These results were 
higher than those obtained for platinum-sensitive and 
-resistant human ovarian cancer cell lines, as well as 
for colon cancer (SW948) and testicular cancer cell 
lines (N-TERA)24.The study of the antitumor activities 
of the mixed ligand platinum(II) oxadiazoline 
complexes with hexamethylenetetramine and 7-nitro-
1,3,5-triazaadamantane on human cancer cell lines 
HeLa and A549 showed that the IC50 was ranged from 
2.5 to 10 µM and some complexes were more 
effective than cisplatin34. It is clear that cisplatin 
showed cytotoxicity in MCF7 cells and the calculated 
IC50 was 5.75±0.07 µM
35. Similar to our results, 
platinum(II) complexes with isoniazid-derived 
 
 
Fig. 6 — Molecular electrostatic potential map of the platinum(II) 
pincer 3d 
 
Table 4 — The antibacterial activities of the tested compounds 3a-d against different human pathogens and compared to  
control antibiotic 
Tested bacteria Diameter of inhibition zone (mm) 
 3a 3b 3c 3d 
Escherichia coli 13.2±0.19 11.4±0.99 11.2±0.99 7.2±1.6 
Klebsiella pneumoniae 12.5±0.52 11.1±1.59 11.0±1.14 7.5±1.67 
Salmonella enterica 11.2±0.22 11.1±2.03 11.7±1.09 9.2±1.26 
Pseudomonas aeruginosa 10.5±0.46 11.4±1.40 10.9±1.17 10.5±0.77 
Proteus mirabilis 10.5±0.43 11.3±2.00 10.5±0.43 7.5±0.45 
Enterococcus faecalis 17.5±0.67 17.3±1.0 7 19.5±0.67 9.15±0.74 
Staphylococcus aureus 16.5±0.64 17.2±0.19 19.2±1.14 9.12±0.14 
MRSA 17.2±0.33 17.5±0.52 22.5±2.50 8.5±0.32 
MRSA: Methicillin-resistant Staphylococcus aureus, 15mg per disc 
 
Table 5 — Antifungal activity of complexes 3c and 3d compared to Amphotericin B 
Tested fungi Diameter of inhibition zone (mm) MIC 
 3c 3d Amphotericin B (Control) 3c 3d 
C. albicans ATCC 90028 15.4 ±1.3 17.3 ±1.4 21. 1 0. 05* 0. 05* 
C. tropicals ATCC 750 17.1±1.9 14.1 ±1.7 11.9 0.10* 0.10* 
MIC of control 1-6x10-4 µM, * sigificant results compared to control 
 
Table 6 — MIC, Toxicity (LD50) and antitumor activity of the tested complexes 3a-d compared to positive control 
Tested compound MIC (µM) Toxicity (LD50, µM) Antitumor activity (IC50, µM) 
MRSA E. faecalis Human colon HCT116 Human breast(MCF-7) 
3a 0. 03* 0. 07* >0.87 2.700 3.955* 
3b  0. 06* 0. 06* >0.82 2.426 2.426* 
3c 0. 11 0. 05* >0.68 1.889* 2.462* 
3d 0. 20* 0.10* 0.62* 1.850* 2.775 
Control# 0.14 0.02 0.88 2.970 3.331 
#Control was either Ampicillin in case of bacteria, CuSO4 in case of toxicity, and cisplatin in case of antitumor activity, * significant 
results compared to control 
 




compound possess both antitumor and antimicrobial 
activities where they inhibited proliferation of  
human breast cancer (MCF-7 and SKBR-3),  
human melanoma (A375), lung adenocarcinoma cells 
(NCI-H1573) and their antibacterial activity were 
against E. coli, K. pneumoniae, S. aureus and  
C. albicans strains36. 
 
DNA binding studies 
The majority of chemotherapeutic platinum(II) 
complexes establish their anticancer activity through 
mechanisms involving interactions with DNA37. 
Therefore, we investigated the ability of our 
platinum(II) complexes 3a-d to interact with DNA. 
The binding constants of the complexes were obtained 
using their spectroscopic responses with variant 
concentrations of the ct-DNA. In general, the 
absorption spectra of 3a-d with the increasing 
concentration of ct-DNA showed similar patterns 
(Fig. 7). All complexes 3a-d displayed hyperchromic 
response at ca. 270 nm with no shift in 3c and 3d 
while blue shifts were noted in 3a and 3b. The Kb 
values were determined for the complexes as 
described in the experimental section and the data 
were summarized in Table 7. 
The data indicates that the binding affinities of 3c 
and 3b are higher than that of 3a and 3d. For 3c, this 
observation can be rationalized by the presence of the 
phenyl groups which may contribute to the binding by 
their pi-involved interactions. Intercalation binding 
mode is suggested for our complexes based on the 
changes of absorbance, as well as the values of 
binding constants (Kb) of platinum(II) complexes and 
ct-DNA38. To confirm the mode of interaction, 
changes in the viscosity can be used as a good 
indication. Generally, a classical intercalative DNA 
binding causes an increase in DNA viscosity due to 
the lengthening of DNA helix, which is caused by an 
increase in the separation of base pairs at interaction 
sites and an increase in overall double helix length39. 
The relative viscosity of DNA in Tris-HCl buffer was 
determined by adding an increasing concentration of 
the complexes 3a-d from (0-200 μM), while the  
ct-DNA concentration (200 μM) was kept constant. 
The effect of increasing the concentration of 
platinum(II) complexes on the viscosity of DNA at  
25 °C is illustrated in Supplementary Data, Fig. S2. 
The results confirmed that the intercalative mode of 
binding exists between all platinum(II) complexes  
3a-d and ct-DNA. 
 
Molecular docking with DNA 
The molecular docking scores (Table 7) suggested 
that 3c have the best score which is in agreement with 
the experimental binding constants. Platinum(II) 
complexes 3a-d contain isoindole fragment which is 
believed to be interacting with DNA and the side-
chains seem to influence the isoindole interaction by 
their steric bulkiness and/or electronic nature. 
According to the docking results, all complexes show 
an intercalation mode of binding via the isoindole 
fragment (Fig. 8). However, complexes 3c and 3b 
established pi-pi stacking with both DNA strand  
(A and B) while 3a and 3d complexes establish their 
stacking only with one strand of DNA(A) (Fig. 8 and 
Table 8). Finally for the purpose of comparison, the 
different biological properties were scaled by dividing 
 
 
Fig. 7 — Spectral responses of 3b while increasing the 
concentration of ct-DNA 
 
Table 7 — Binding constant (Kb), spectroscopic effect at 270 nm 
and docking scores 




effect at 270 nm 
Docking 
scores 
3a 6.67 (±0.07) Blue shift ‒ 4.33 
3b 8.00 (±0.03) Blue shift ‒ 4.27 
3c 8.33 (±0.06) No shift ‒ 5.27 




Fig. 8 — 2D and 3D views of the interactions between 
platinum(II) complexes 3a-d and DNA as obtained from the 
docking studies 




all the other values within a property on the best 
value; hence the best complex would have a  
scaled value equal to one. All the different scaled 
properties for all complexes are plotted in Fig. 9. It is 




The reaction between cis/trans-[PtCl2(N≡CR)2] 1 
and 1,3-diiminoisoindoline 2 afforded symmetrical 
(1,3,5,7,9-pentaazanona-1,3,6,8-tetraenato) Pt(II) 
complexes 3a-d in a base-free protocol in contrast to 
their nickel(II) analogues. Complex 3d was optimized 
using DFT at the B3LYP/LANL2DZ/6-311G* level 
of theory and its electronics structure was described in 
terms of the distribution of the HOMO and LUMO. 
GIAO method was used to calculate the NMR spectra, 
the correlations between the calculated and 
experimental chemical shifts are 0.9947 for 1H and 
0.9968 for 13C. MEP shows that the most positive 
(blue) regions are localized on the hydrogen atoms of 
the phenyl groups showing electrophilic reactivity; 
whereas the most negative (red) regions are observed 
around the chloride atom. The antimicrobial studies 
revealed that the platinum(II) complexes 3a-d showed 
good activities against gram positive bacteria and 
moderate activities against gram negative bacteria. 
The anticancer studies of these complexes against the 
two cisplatin-resistant cell lines showed their potential 
as anticancer drugs. The DNA-binding studies and the 
molecular docking indicated a strong binding of the 
complexes toward ct-DNA through intercalation 
mode of bonding by their isoindole unit. Among the 
studied complexes, complex 3c has IC50, binding 
constant to ct-DNA and docking score values better 
than complexes (3a, 3b, 3d) which may result from 
the presence of the phenyl rings in the side chains on 
the ligand. The notable variations in the IC50 values, 
binding constants and molecular docking scores 
indicate the significance of the side-chains on  
the ligands in tuning these properties. Moreover,  
the side-chains can be used to modify some chemical 
and physical properties of this class of platinum(II) 
complexes which can help in some other aspects such 
as the solubility and cell membrane transmittance. 
 
Supplementary Data 
Supplementary data associated with this article  
are available in the electronic form at 
http://nopr.niscair.res.in/jinfo/ijca/IJCA_60A(04)519-
530_SupplData.pdf. 
Table 8 — Different interactions of the platinum(II) complexes 3a-d with ct-DNA in accordance to the molecular docking study 
Complex Fragment involved from the complex Receptor in the DNA Mode of interaction Distance (Ǻ) E (kcal/mol) 
3a  5-ring isoindole 6-ring DC111 (B) pi-pi 2.83 -0.0 
3b 
5-ring isoindole 6-ring DT112 (B)  pi-pi 3.63 -0.0 
5-ring isoindole 6-ring DC111 (B)  Pi-pi  3.05 -0.0 
5-ring isoindole 6-ring DA11 (A)  pi-pi 3.13 -0.0 
5-ring isoindole 6-ring DG12 (A)  pi-pi 3.01 -0.0 
6-ring isoindole 6-ring DG12 (A)  pi-pi 3.24 -0.0 
3c 
5-ring isoindole 6-ring DC111 (B)  pi-pi 3.69 -0.0 
5-ring isoindole 6-ring DT110 (B)  pi-pi 3.64 -0.0 
5-ring isoindole 6-ring DG12 (A)  pi-pi 3.80 -0.0 
6-ring side chain  6-ring DA13 (A)  pi-pi 3.74 -0.0 
6-ring side chain  6-ring DA13 (A)  pi-pi 3.28 -0.0 
3d 
5-ring isoindole 5-ring DC11 (A)  pi-pi 2.52 -0.0 
5-ring isoindole 5-ring DT12 (A)  pi-pi 3.93 -0.0 
5-ring isoindole 6-ring DT12 (A)  pi-pi 3.00 -0.0 
5-ring isoindole 6-ring DT12 (A)  pi-pi 3.77 -0.0 
6-ring isoindole 5-ring DT12 (A)  pi-pi 3.45 -0.0 




Fig. 9 — Comparison of the biological properties (scaled values) 
for complexes 3a-d 
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